The cost-effectiveness of periodic safety update reports for biologicals in Europe
Bouvy JC, Ebbers HC, Schellekens H, Koopmanschap MA

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1038/clpt.2013.13

Indexing Status
Subject indexing assigned by NLM

MeSH
Adverse Drug Reaction Reporting Systems /economics /statistics & numerical data; Biological Products /adverse effects /therapeutic use; Bone Morphogenetic Protein 2 /adverse effects /therapeutic use; Botulinum Toxins /adverse effects /therapeutic use; Cost-Benefit Analysis; Europe; European Union; Humans; Legislation, Drug; Markov Chains; Off-Label Use; Pharmacovigilance; Quality-Adjusted Life Years

AccessionNumber
22013014484

Date bibliographic record published
01/05/2013